Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types

Molecular Pharmaceutics

Volumn 11, Issue 2, 2014, Pages 580-587

  Dam, Duncan Hieu M ^a   Culver, Kayla S B ^b   Odom, Teri W ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

anticancer agents; aptamers; gold nanostars; nucleolin

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; AS 1411; CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; GOLD NANOPARTICLE; GOLD NANOSTAR; GRAFTING APTAMER; MESSENGER RNA; NUCLEOLIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; AGRO 100; GOLD; METAL NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEMBRANE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; CELL LINE; CHEMISTRY; DOWN REGULATION; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PROTO ONCOGENE; TUMOR CELL LINE;

APTAMERS, NUCLEOTIDE; CELL LINE; CELL LINE, TUMOR; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; GENES, BCL-2; GOLD; HUMANS; METAL NANOPARTICLES; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; RNA-BINDING PROTEINS;

EID: 84893318773     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4005657     Document Type: Article

References (37)

1. Harris, M. Monoclonal antibodies as therapeutic agents for cancer Lancet Oncol. 2004, 5, 292-302 (Pubitemid 38541581)
2. Brown, K. C. New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries Curr. Opin. Chem. Biol. 2000, 4, 16-21 (Pubitemid 30098667)
3. Nahta, R.; Hung, M. C.; Esteva, F. J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res. 2004, 64, 2343-2346 (Pubitemid 38523885)
4. Ellis, L. M.; Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity Nat. Rev. Cancer 2008, 8, 579-91
5. Sawyers, C. Targeted cancer therapy Nature 2004, 432, 294-7 (Pubitemid 39551656)
6. Dexter, D. L.; Leith, J. T. Tumor heterogeneity and drug resistance J. Clin. Oncol. 1986, 4, 244-57 (Pubitemid 16161042)
7. Shipitsin, M.; Campbell, L. L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; Halushka, M. K.; Sukumar, S.; Parker, L. M.; Anderson, K. S.; Harris, L. N.; Garber, J. E.; Richardson, A. L.; Schnitt, S. J.; Nikolsky, Y.; Gelman, R. S.; Polyak, K. Molecular definition of breast tumor heterogeneity Cancer Cell 2007, 11, 259-73 (Pubitemid 46349843)
8. Smith, I.; Procter, M.; Gelber, R. D.; Guillaume, S.; Feyereislova, A.; Dowsett, M.; Goldhirsch, A.; Untch, M.; Mariani, G.; Baselga, J.; Kaufmann, M.; Cameron, D.; Bell, R.; Bergh, J.; Coleman, R.; Wardley, A.; Harbeck, N.; Lopez, R. I.; Mallmann, P.; Gelmon, K.; Wilcken, N.; Wist, E.; Sanchez Rovira, P.; Piccart-Gebhart, M. J. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 2007, 369, 29-36 (Pubitemid 46039831)
9. Siegel, R.; DeSantis, C.; Virgo, K.; Stein, K.; Mariotto, A.; Smith, T.; Cooper, D.; Gansler, T.; Lerro, C.; Fedewa, S.; Lin, C.; Leach, C.; Cannady, R. S.; Cho, H.; Scoppa, S.; Hachey, M.; Kirch, R.; Jemal, A.; Ward, E. Cancer treatment and survivorship statistics, 2012 CA Cancer J. Clin. 2012, 62, 220-41
10. Bates, P. J.; Laber, D. A.; Miller, D. M.; Thomas, S. D.; Trent, J. O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer Exp. Mol. Pathol. 2009, 86, 151-164
11. Borer, R. A.; Lehner, C. F.; Eppenberger, H. M.; Nigg, E. A. Major Nucleolar Proteins Shuttle between Nucleus and Cytoplasm Cell 1989, 56, 379-390
12. Ginisty, H.; Sicard, H.; Roger, B.; Bouvet, P. Structure and functions of nucleolin J. Cell Sci. 1999, 112, 761-772 (Pubitemid 29179310)
13. Hovanessian, A. G.; Soundaramourty, C.; El Khoury, D.; Nondier, I.; Svab, J.; Krust, B. Surface Expressed Nucleolin Is Constantly Induced in Tumor Cells to Mediate Calcium-Dependent Ligand Internalization PloS One 2010, 5, e15787
14. Soundararajan, S.; Wang, L.; Sridharan, V.; Chen, W. W.; Courtenay-Luck, N.; Jones, D.; Spicer, E. K.; Fernandes, D. J. Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells Mol. Pharmacol. 2009, 76, 984-991
15. Keefe, A. D.; Pai, S.; Ellington, A. Aptamers as therapeutics Nat. Rev. Drug Discovery 2010, 9, 537-550
16. Ireson, C. R.; Kelland, L. R. Discovery and development of anticancer aptamers Mol. Cancer Ther. 2006, 5, 2957-62 (Pubitemid 46092036)
17. Nimjee, S. M.; Rusconi, C. P.; Sullenger, B. A. Aptamers: An emerging class of therapeutics Annu. Rev. Med. 2005, 56, 555
18. Otake, Y.; Soundararajan, S.; Sengupta, T. K.; Kio, E. A.; Smith, J. C.; Pineda-Roman, M.; Stuart, R. K.; Spicer, E. K.; Fernandes, D. J. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA Blood 2007, 109, 3069-3075 (Pubitemid 46482108)
19. Sengupta, T. K.; Bandyopadhyay, S.; Fernandes, D. J.; Spicer, E. K. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization J. Biol. Chem. 2004, 279, 10855-10863 (Pubitemid 38401575)
20. Soundararajan, S.; Chen, W. W.; Spicer, E. K.; Courtenay-Luck, N.; Fernandes, D. J. The nucleolin targeting aptamer AS1411 destabilizes bcl-2 messenger RNA in human breast cancer cells Cancer Res. 2008, 68, 2358-2365 (Pubitemid 351521810)
21. Stuart, R. K.; Stockerl-Goldstein, K.; Cooper, M.; Devetten, M.; Herzig, R.; Medeiros, B.; Schiller, G.; Wei, A.; Acton, G.; Rizzieri, D. Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML) J. Clin. Oncol. 2009, 27, 7019
22. Miller, D. M.; Laber, D. A.; Bates, P. J.; Trent, J. O.; Taft, B. S.; Kloecker, G. H. Extended phase I study of AS1411 in renal and non-small cell lung cancers Ann. Oncol. 2006, 17, 147-148
23. Kim, B. Y.; Rutka, J. T.; Chan, W. C. Nanomedicine N. Engl. J. Med. 2010, 363, 2434-43
24. Peer, D.; Karp, J. M.; Hong, S.; FarokHzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2, 751-760 (Pubitemid 350223348)
25. Girvan, A. C.; Teng, Y.; Casson, L. K.; Thomas, S. D.; Juliger, S.; Ball, M. W.; Klein, J. B.; Pierce, W. M., Jr.; Barve, S. S.; Bates, P. J. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin Mol. Cancer Ther. 2006, 5, 1790-9 (Pubitemid 44323247)
26. Dam, D. H.; Lee, J. H.; Sisco, P. N.; Co, D. T.; Zhang, M.; Wasielewski, M. R.; Odom, T. W. Direct observation of nanoparticle-cancer cell nucleus interactions ACS Nano 2012, 6, 3318-26
27. Seferos, D. S.; Prigodich, A. E.; Giljohann, D. A.; Patel, P. C.; Mirkin, C. A. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids Nano Lett. 2009, 9, 308-11
28. Busbee, B. D.; Obare, S. O.; Murphy, C. J. An improved synthesis of high-aspect-ratio gold nanorods Adv. Mater. 2003, 15, 414
29. Murphy, C. J.; Gole, A. M.; Stone, J. W.; Sisco, P. N.; Alkilany, A. M.; Goldsmith, E. C.; Baxter, S. C. Gold nanoparticles in biology: beyond toxicity to cellular imaging Acc. Chem. Res. 2008, 41, 1721-30
30. Jana, N. R.; Gearheart, L.; Murphy, C. J. Seeding growth for size control of 5-40 nm diameter gold nanoparticles Langmuir 2001, 17, 6782-6786 (Pubitemid 35330558)
31. Xie, J. P.; Lee, J. Y.; Wang, D. I. C. Seedless, surfactantless, high-yield synthesis of branched gold nanocrystals in HEPES buffer solution Chem. Mater. 2007, 19, 2823-2830 (Pubitemid 46904018)
32. Massich, M. D.; Giljohann, D. A.; Schmucker, A. L.; Patel, P. C.; Mirkin, C. A. Cellular response of polyvalent oligonucleotide-gold nanoparticle conjugates ACS nano 2010, 4, 5641-6
33. Reyes-Reyes, E. M.; Teng, Y.; Bates, P. J. A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism Cancer Res. 2010, 70, 8617-8629
34. Kim, J. A.; Aberg, C.; Salvati, A.; Dawson, K. A. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population Nat Nanotechnol. 2012, 7, 62-8
35. Lam, M.; Dubyak, G.; Chen, L.; Nunez, G.; Miesfeld, R. L.; Distelhorst, C. W. Evidence That Bcl-2 Represses Apoptosis by Regulating Endoplasmic Reticulum-Associated Ca2+ Fluxes Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 6569-6573
36. Schwartz, G. K.; Shah, M. A. Targeting the cell cycle: a new approach to cancer therapy J. Clin. Oncol. 2005, 23, 9408-21
37. Dapic, V.; Bates, P. J.; Trent, J. O.; Rodger, A.; Thomas, S. D.; Miller, D. M. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications Biochemistry 2002, 41, 3676-3685